Skip to content
OpenCapital
Get started

Iovance Biotherapeutics, Inc. IOVA Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$71.4MMiss by $6.4M
EPS-$0.19In line
Revenue estimate$77.8M
EPS estimate-$0.19

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$87.7M
EPS estimate-$0.17

Financials

Q1 2026

Income statement

See full
Revenue$71.4M+44.8%
Gross profit$28.9M+338%
Operating income-$81.0M+33.1%
Net income-$79.0M+32.0%
EPS (diluted)-$0.19+47.2%

Balance sheet

See full
Cash & equivalents$196.5M+14.5%
Total debt$46.8M-11.3%
Total equity$721.8M-6.0%
Total assets$925.7M-4.2%

Cash flow

See full
Operating cash flow-$72.1M+30.5%
CapEx$6.6M+6.4%
Free cash flow-$78.7M+28.4%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$2.19B+122%
Enterprise value$2.04B+125%
P/S7.7×+3.6×

Profitability

See full
Gross margin36.7%+4.1pp
Operating margin-127.2%-31.0pp
Net margin-123.9%-28.4pp
FCF margin-106.8%-27.5pp

Returns & leverage

See full
Return on equity-47.5%-3.7pp
Debt / equity0.1×0.0×
Current ratio3.6×-0.6×

Segments

By product

See full
Amtagvi$60.2M+38.2%
Proleukin$11.2M+94.8%

By segment

See full
Single Reportable$71.4M+44.8%

Versus estimates

Revenue

Q1 2026$71.4MMiss by $6.4M
Q4 2025$86.7MBeat by $6.0MQ3 2025$67.5MMiss by $14.7MQ2 2025$60.0MMiss by $18.4MQ1 2025$49.3MMiss by $33.1MQ4 2024$73.7MBeat by $1.5M

Diluted EPS

Q1 2026-$0.19In line
Q4 2025-$0.18Beat by $0.04Q3 2025-$0.25Beat by $0.04Q2 2025-$0.33Miss by $0.04Q1 2025-$0.36Miss by $0.11Q4 2024-$0.26In line

Ask the moment Iovance Biotherapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Iovance Biotherapeutics, Inc. report Q1 2026 earnings?
Iovance Biotherapeutics, Inc. (IOVA) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Iovance Biotherapeutics, Inc.'s Q1 2026 revenue and EPS?
Iovance Biotherapeutics, Inc. reported revenue of $71.4M and eps of $-0.19 for Q1 2026.
Did Iovance Biotherapeutics, Inc. beat estimates in Q1 2026?
Revenue missed the consensus estimate of $77.8M by $6.4M. EPS beat the consensus estimate of $-0.19 by $0.00.
How did Iovance Biotherapeutics, Inc.'s Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 44.8% from $49.3M a year earlier and eps grew 47.2% from $-0.36.
Where can I find Iovance Biotherapeutics, Inc.'s Q1 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-056782) and the 10-Q periodic report (0001104659-26-056778) directly on SEC EDGAR. The filing index links above go to sec.gov.